低分子肝素依诺肝素联合标准治疗小细胞肺癌的随机III期试验:RASTEN研究
RASTEN研究是一项随机、多中心、开放标签III期试验,纳入390例新诊断小细胞肺癌患者,比较标准治疗联合超预防剂量依诺肝素(1 mg/kg)与单纯标准治疗的疗效。主要终点总生存(OS)无显著差异(HR 1.11,95%CI 0.89-1.38,P=0.36),无进展生存(PFS)亦无差异(HR 1.18,95%CI 0.95-1.46,P=0.14)。静脉血栓栓塞(VTE)发生率在依诺肝素组显著降低(HR 0.31,95%CI 0.11-0.84,P=0.02),但出血事件更常见。
要点
- 超预防剂量依诺肝素未改善小细胞肺癌患者的总生存和无进展生存。
- 依诺肝素显著降低VTE发生率,但出血事件增加。
- 不推荐常规在小细胞肺癌治疗中添加低分子肝素。
核心结论
- 在标准治疗基础上加用超预防剂量依诺肝素未能改善小细胞肺癌患者的总生存。
- 尽管依诺肝素显著降低了VTE发生率,但出血事件更频繁。
- 不推荐常规在小细胞肺癌患者的管理中加入低分子肝素。
研究设计与样本
- 随机、多中心、开放标签III期试验(RASTEN)。
- 纳入新诊断小细胞肺癌患者390例,随机分配至依诺肝素组(1 mg/kg)联合标准治疗或单纯标准治疗。
- 最终分析纳入依诺肝素组186例和对照组191例。
- 主要终点为总生存(OS),次要终点包括无进展生存(PFS)、VTE发生率和出血事件。
主要发现
- 依诺肝素组与对照组相比,OS无显著差异(HR 1.11;95%CI 0.89-1.38;P=0.36)。
- PFS无显著差异(HR 1.18;95%CI 0.95-1.46;P=0.14)。
- 局限期和广泛期亚组分析均未显示依诺肝素降低死亡率。
- VTE发生率在依诺肝素组显著降低(HR 0.31;95%CI 0.11-0.84;P=0.02)。
- 出血事件在依诺肝素组更频繁,但致死性出血在两组均有发生。
关键数值与推荐
- 依诺肝素用法为超预防剂量1 mg/kg。
- VTE风险降低的HR为0.31(95%CI 0.11-0.84;P=0.02)。
- OS的HR为1.11(95%CI 0.89-1.38;P=0.36)。
- PFS的HR为1.18(95%CI 0.95-1.46;P=0.14)。
临床怎么用
- 不推荐常规在小细胞肺癌标准治疗中加用低分子肝素。
- 对于VTE高风险的小细胞肺癌患者,可考虑使用低分子肝素预防,但需权衡出血风险。
- 需进一步研究预测VTE和低分子肝素相关出血的生物标志物。
局限性
- 开放标签设计可能引入偏倚。
- 研究人群为小细胞肺癌,结果可能不适用于其他肿瘤类型。
- 未报告其他潜在局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coagulation activation and venous thromboembolism (VTE) are hallmarks of malignant disease and represent a major cause of morbidity and mortality in cancer. Coagulation inhibition with low-molecular-weight heparin (LMWH) may improve survival specifically in small-cell lung cancer (SCLC) patients by preventing VTE and tumor progression; however, randomized trials with well-defined patient populations are needed to obtain conclusive data. The aim of RASTEN was to investigate the survival effect of LMWH enoxaparin in a homogenous population of SCLC patients. PATIENTS AND METHODS: We carried out a randomized, multicenter, open-label trial to investigate the addition of enoxaparin at a supraprophylactic dose (1 mg/kg) to standard treatment in patients with newly diagnosed SCLC. The primary outcome was overall survival (OS), and secondary outcomes were progression-free survival (PFS), incidence of VTE and hemorrhagic events. RESULTS: In RASTEN, 390 patients were randomized over an 8-year period (2008-2016), of whom 186 and 191 were included in the final analysis in the LMWH and control arm, respectively. We found no evidence of a difference in OS or PFS by the addition of enoxaparin [hazard ratio (HR), 1.11; 95% confidence interval (CI) 0.89-1.38; P = 0.36 and HR, 1.18; 95% CI 0.95-1.46; P = 0.14, respectively]. Subgroup analysis of patients with limited and extensive disease did not show reduced mortality by enoxaparin. The incidence of VTE was significantly reduced in the LMWH arm (HR, 0.31; 95% CI 0.11-0.84; P = 0.02). Hemorrhagic events were more frequent in the LMWH-treated group but fatal bleedings occurred in both arms. CONCLUSION: LMWH enoxaparin in addition to standard therapy did not improve OS in SCLC patients despite being administered at a supraprophylactic dose and despite resulting in a significant reduction in VTE incidence. Addition of LMWH cannot be generally recommended in the management of SCLC patients, and predictive biomarkers of VTE and LMWH-associated bleeding in cancer patients are warranted.
引用
- Ek L, Gezelius E, Bergman B, et al. Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial. Ann Oncol. 2018. PMID: 29106448. doi:10.1093/annonc/mdx716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。